In the US, IMBRUVICA (ibrutinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Chronic Lymphocytic Leukemia, Graft-versus-host disease, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma and Waldenström Macroglobulinemia.
Ingredient matches for IMBRUVICA
Ibrutinib is reported as an ingredient of IMBRUVICA in the following countries:
- Croatia (Hrvatska)
- United Kingdom
- United States